uniQure N.V. Net Change in Cash
uniQure N.V. (QURE) reported Net Change in Cash of $59.73 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-05-05
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $59.73M, a 2.41% increase year-over-year.
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $58.33M, a 3361.66% increase year-over-year.
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $1.69M.
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$74.15M.
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$78.53M.
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$84.22M, a 729.83% decline from fiscal 2023.
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $13.37M.
- uniQure N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$328.18M, a 205.30% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-03-31 | $59.73M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | -$78.53M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $438.22M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $94.94M 10-Q · filed 2025-07-29 | |||
| 2025-03-31 | $58.33M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$84.22M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $8.54M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $46.49M 10-Q · filed 2025-07-29 | |||
| 2024-03-31 | $1.69M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $13.37M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $1.46M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $285.60M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | -$74.15M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$328.18M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$115.93M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$55.69M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | -$31.27M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $311.67M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $333.59M 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $432.48M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $15.85M 10-Q · filed 2022-05-02 | |||
| 2020-12-31 | -$133.05M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | -$98.52M 10-Q · filed 2021-10-25 | |||
| 2020-06-30 | -$63.78M 10-Q · filed 2021-07-26 | |||
| 2020-03-31 | -$35.78M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $143.38M 10-K · filed 2022-02-25 | |||
| 2019-09-30 | $168.74M 10-Q · filed 2020-10-27 | |||
| 2019-06-30 | -$50.31M 10-Q · filed 2020-07-30 | |||
| 2019-03-31 | -$25.63M 10-Q · filed 2020-04-29 | |||
| 2018-12-31 | $75.49M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $80.15M 10-Q · filed 2019-10-28 | |||
| 2018-06-30 | $99.79M 10-Q · filed 2019-07-29 | |||
| 2018-03-31 | -$18.53M 10-Q · filed 2019-04-29 | |||
| 2017-12-31 | $27.53M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | -$42.92M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | -$28.36M 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | -$12.22M 10-Q · filed 2018-04-30 | |||
| 2016-12-31 | -$88.55M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |